Apellis to be Acquired by Biogen for $5.6 Billion in Cash and CVRs

summarizeSummary

Apellis Pharmaceuticals has entered into a definitive merger agreement to be acquired by Biogen Inc. for $41.00 per share in cash plus a contingent value right of up to $4.00 per share, totaling approximately $5.6 billion upfront.

check_boxKey Events

• Definitive Merger Agreement

  Apellis Pharmaceuticals, Inc. has entered into an Agreement and Plan of Merger with Biogen Inc. to be acquired for $41.00 per share in cash, plus one contractual, non-transferable contingent value right (CVR) per share.

• Contingent Value Rights (CVRs)

  Each CVR entitles the holder to receive potential payments of up to an aggregate of $4.00 in cash upon the achievement of specified annual global net sales milestones for SYFOVRE® ($2.00 for $1.5 billion in sales by 2030, and an additional $2.00 for $2.0 billion in sales by 2031, or $4.00 if only the $2.0 billion milestone is met in 2031 and the $1.5 billion milestone was not met).

• Transaction Value and Premium

  The upfront cash consideration for the acquisition is approximately $5.6 billion. The offer represents an 86% premium to the 90-day volume-weighted average stock price and a 35% premium to the 52-week high stock price.

• Board and Insider Support

  Apellis's Board of Directors unanimously recommended the offer. Certain directors, executive officers, and a 10% owner (Morningside Venture Investments, Ltd.), collectively holding approximately 14% of outstanding shares, entered into tender and support agreements.

auto_awesomeAnalysis

This 8-K filing announces a definitive merger agreement under which Biogen Inc. will acquire Apellis Pharmaceuticals. The transaction offers Apellis shareholders a substantial premium, combining a fixed cash payment with potential upside from contingent value rights tied to future sales of SYFOVRE®. This acquisition significantly enhances Biogen's portfolio in immunology and rare diseases while providing a clear exit for Apellis shareholders at a favorable valuation. The unanimous board recommendation and support agreements from key insiders underscore the strategic alignment and likelihood of completion.